Ingalls & Snyder LLC Decreases Holdings in Zoetis Inc. (NYSE:ZTS)

Ingalls & Snyder LLC lowered its holdings in Zoetis Inc. (NYSE:ZTS) by 1.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 13,167 shares of the company’s stock after selling 132 shares during the quarter. Ingalls & Snyder LLC’s holdings in Zoetis were worth $2,145,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Darwin Wealth Management LLC purchased a new stake in Zoetis in the third quarter valued at $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis during the third quarter worth about $33,000. Capital Performance Advisors LLP purchased a new stake in shares of Zoetis in the 3rd quarter valued at about $33,000. Dunhill Financial LLC boosted its position in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the period. Finally, Atlantic Edge Private Wealth Management LLC grew its stake in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after buying an additional 140 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

ZTS has been the subject of several research analyst reports. Stifel Nicolaus decreased their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. UBS Group assumed coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Piper Sandler decreased their target price on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday. Finally, Leerink Partners started coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $214.00.

Zoetis Price Performance

Shares of ZTS opened at $165.28 on Friday. The firm has a market capitalization of $74.57 billion, a PE ratio of 31.07, a P/E/G ratio of 2.77 and a beta of 0.90. The stock’s 50 day moving average is $169.08 and its two-hundred day moving average is $179.08. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. Research analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.21%. Zoetis’s dividend payout ratio is presently 37.59%.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.